Nearly two dozen new fully curated somatic genes and 387 clinical trials included in COSMIC Actionability v8 release
We are pleased to announce the availability of a new release for COSMIC, the Catalogue of Somatic Mutations in Cancer. COSMIC Actionability v8 adds new actionability data to the world’s largest, expert-curated somatic mutation database. The release includes 22 new fully curated somatic genes, 387 new clinical trials, and 166 new oncology drugs.
In this article, we provide a summary of the COSMIC Actionability v8 release highlights.
What is COSMIC?
COSMIC is an expert-curated database encompassing the wide variety of somatic mutation mechanisms causing human cancer. Owned and maintained by the Wellcome Sanger Institute, COSMIC is exclusively licensed through QIAGEN.
COSMIC’s team of variant scientists manually curates key cancer genes to provide in-depth information on mutation distributions and effects. The team relies on a semi-automated curation process of cancer genomes to provide broad somatic annotations toward target discovery and identification of patterns and signatures. To date, COSMIC contains over 23 million somatic mutations associated with human cancers.
What is COSMIC Actionability?
COSMIC Actionability is a standalone product within the COSMIC database that focuses on providing information on the availability and development of drugs targeting somatic mutations in cancer. COSMIC’s certified curation team integrates data from case studies, clinical trials, and regulatory bodies to represent a full picture of the current precision oncology pipeline (from drug development, through safety and clinical phases, to market and repurposing).
Actionability contains information on three core units: mutations, diseases and drugs. By capturing relations between these units, COSMIC’s team identifies existing and upcoming drugs that target specific genetic variants in different cancer types. COSMIC Actionability is a cutting-edge, ‘living-tool’ that provides the most up-to-date data for precision oncology applications.
What’s new in COSMIC v8 Actionability?
- 22 additional fully curated genes: ATR, BCL2, CD33, CDKN2A, CHEK2, ERBB4, FBXW7, GNAS, MAP2K2, MTOR, MYD88, NOTCH1, NTRK1, NTRK2, NTRK3, PALB2, PIK3CB, PTPN11, RAF1, SYK, TERT, VHL.
- 387 new clinical trials: COSMIC Actionability now contains 3,977 trials with results and 5,431 trials with no results. As a result, there is now a total of 9,408 clinical trials.
- 166 new drugs: COSMIC Actionability now contains 1,686 drugs.
- 70 new somatic variants: With the new release, COSMIC Actionability now contains 834 total somatic variants.
→ View the full Actionability v8 release notes here.
Want to know more about COSMIC?
Learn more about COSMIC and how the industry-leading database can help you identify biomarkers, annotate variants, and explore the etiology of human cancers here.
Download COSMIC sample data
See first-hand how COSMIC can be used in your lab and the quality of the database’s content by downloading sample data here.